JP2011529037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529037A5 JP2011529037A5 JP2011519241A JP2011519241A JP2011529037A5 JP 2011529037 A5 JP2011529037 A5 JP 2011529037A5 JP 2011519241 A JP2011519241 A JP 2011519241A JP 2011519241 A JP2011519241 A JP 2011519241A JP 2011529037 A5 JP2011529037 A5 JP 2011529037A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- alkyl
- groups
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000004432 carbon atom Chemical group C* 0.000 claims 24
- 125000001424 substituent group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 14
- 239000000651 prodrug Substances 0.000 claims 14
- -1 monoalkylamino group Chemical group 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000003277 amino group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004442 acylamino group Chemical group 0.000 claims 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 4
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 108090000312 Calcium Channels Proteins 0.000 claims 2
- 102000003922 Calcium Channels Human genes 0.000 claims 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- OGCMQEYJLBFBKZ-UHFFFAOYSA-N 2-[4-[2,6-dichloro-4-(trifluoromethoxy)anilino]phenyl]-n-(2-hydroxyethyl)acetamide Chemical compound C1=CC(CC(=O)NCCO)=CC=C1NC1=C(Cl)C=C(OC(F)(F)F)C=C1Cl OGCMQEYJLBFBKZ-UHFFFAOYSA-N 0.000 claims 1
- GQLSABOKEQDLSD-UHFFFAOYSA-N 2-[4-[2,6-dichloro-4-(trifluoromethyl)anilino]phenyl]-n-(2-hydroxyethyl)acetamide Chemical compound C1=CC(CC(=O)NCCO)=CC=C1NC1=C(Cl)C=C(C(F)(F)F)C=C1Cl GQLSABOKEQDLSD-UHFFFAOYSA-N 0.000 claims 1
- VXBVFBWALLHUCE-UHFFFAOYSA-N 2-[[2-[4-(3,5-dichloroanilino)phenyl]acetyl]amino]acetic acid Chemical compound C1=CC(CC(=O)NCC(=O)O)=CC=C1NC1=CC(Cl)=CC(Cl)=C1 VXBVFBWALLHUCE-UHFFFAOYSA-N 0.000 claims 1
- SNWSKHQPRZVNIJ-UHFFFAOYSA-N 2-[[2-[5-(3,5-dichloroanilino)-2-fluorophenyl]acetyl]amino]acetic acid Chemical compound C1=C(F)C(CC(=O)NCC(=O)O)=CC(NC=2C=C(Cl)C=C(Cl)C=2)=C1 SNWSKHQPRZVNIJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- LEZFMENAFUAIPM-UHFFFAOYSA-N 5-[2,6-dichloro-4-(trifluoromethyl)anilino]-2-fluoro-n-(2-hydroxyethyl)benzamide Chemical compound C1=C(F)C(C(=O)NCCO)=CC(NC=2C(=CC(=CC=2Cl)C(F)(F)F)Cl)=C1 LEZFMENAFUAIPM-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 108091008604 NGF receptors Proteins 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 102100034360 Potassium voltage-gated channel subfamily KQT member 3 Human genes 0.000 claims 1
- 102000002294 Purinergic P2X Receptors Human genes 0.000 claims 1
- 108010000836 Purinergic P2X Receptors Proteins 0.000 claims 1
- 101710084141 Synaptic vesicle glycoprotein 2A Proteins 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000000801 calcium channel stimulating agent Substances 0.000 claims 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 claims 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940125400 channel inhibitor Drugs 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- BICBNNOQHPXLSI-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-[3-(2,4,6-trichloroanilino)phenyl]acetamide Chemical compound OCCNC(=O)CC1=CC=CC(NC=2C(=CC(Cl)=CC=2Cl)Cl)=C1 BICBNNOQHPXLSI-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 239000004036 potassium channel stimulating agent Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0813403.3A GB0813403D0 (en) | 2008-07-22 | 2008-07-22 | Potassium ion channel modulators & uses thereof |
| GB0813403.3 | 2008-07-22 | ||
| PCT/GB2009/050887 WO2010010380A1 (en) | 2008-07-22 | 2009-07-20 | Potassium ion channel modulators & uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529037A JP2011529037A (ja) | 2011-12-01 |
| JP2011529037A5 true JP2011529037A5 (https=) | 2012-06-28 |
Family
ID=39737453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519241A Pending JP2011529037A (ja) | 2008-07-22 | 2009-07-20 | カリウムイオンチャネル調節剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9464052B2 (https=) |
| EP (1) | EP2310357B1 (https=) |
| JP (1) | JP2011529037A (https=) |
| CN (1) | CN102159535A (https=) |
| DK (1) | DK2310357T3 (https=) |
| GB (1) | GB0813403D0 (https=) |
| WO (1) | WO2010010380A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| US8624063B2 (en) | 2009-06-30 | 2014-01-07 | Wisconsin Alumni Research Foundation | Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing |
| JP2013531687A (ja) | 2010-07-16 | 2013-08-08 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリジン化合物 |
| AU2011303597A1 (en) | 2010-09-17 | 2013-04-11 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
| CA2859842C (en) * | 2012-03-14 | 2016-11-08 | Sinochem Corporation | Substitute diphenylamine compounds use thereof as antitumor agents |
| WO2013136170A1 (en) | 2012-03-16 | 2013-09-19 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
| WO2017156519A1 (en) * | 2016-03-11 | 2017-09-14 | The Board Of Trustees Of The University Of Illinois | Small-molecules active against gram-negative bacteria |
| US11690876B2 (en) | 2017-05-10 | 2023-07-04 | University Of Rochester | Methods of treating neuropsychiatric disorders |
| IL273893B2 (en) * | 2017-10-09 | 2025-11-01 | Univ Ramot | Modulators of potassium ion and trpv1 channels and uses thereof |
| US10526278B2 (en) | 2017-10-19 | 2020-01-07 | Wisconsin Alumni Research Foundation | Inhibitors of quorum sensing receptor LasR |
| EP4025300A1 (en) * | 2019-09-03 | 2022-07-13 | Salzman Group Ltd. | Atp-regulated potassium channel openers comprising guanidine and uses thereof |
| BR112022004847A2 (pt) * | 2019-09-17 | 2022-06-07 | Knopp Biosciences Llc | Método para tratar uma doença ou distúrbio de neurodesenvolvimento |
| WO2022157686A1 (en) * | 2021-01-22 | 2022-07-28 | Ildong Pharmaceutical Co., Ltd. | Inhibitors of anoctamin 6 protein and uses thereof |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| EP4294806A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| MX2023010976A (es) * | 2021-03-19 | 2023-12-07 | Xyzagen Inc | Profármacos de abridores de canales kv7. |
| AU2022420827A1 (en) | 2021-12-22 | 2024-06-13 | Augustine Therapeutics | Compounds and use thereof as hdac6 inhibitors |
| WO2023139581A1 (en) * | 2022-01-18 | 2023-07-27 | Bsense Bio Therapeutics Ltd. | Modulators of a potassium channel and of trpv1 channel and uses thereof |
| CN120435316A (zh) * | 2022-08-30 | 2025-08-05 | 拜奥海芬治疗学有限公司 | 包括金属通道激活剂和nmda受体拮抗剂的组合疗法 |
| IT202200024948A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio KV7.2/KV7.3 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1882286A (en) * | 1929-07-17 | 1932-10-11 | Gen Aniline Works Inc | Arylamides of meta-hydroxy-diarylamine-carboxylic acids and process of making same |
| BE590607A (https=) | 1960-02-24 | |||
| US3413313A (en) * | 1964-06-18 | 1968-11-26 | Parke Davis & Co | Anthranilic acid compounds and methods for their production |
| CA1087186A (en) * | 1977-01-21 | 1980-10-07 | Kurt H. G. Pilgram | Cycloalkane-carboxanilides |
| US4181519A (en) * | 1977-01-21 | 1980-01-01 | Shell Oil Company | Diphenylamine derivative herbicides |
| ZA865090B (en) | 1985-07-22 | 1988-02-24 | Riker Laboratories Inc | Substituted di-t-butylphenols |
| IL86462A (en) * | 1987-05-29 | 1992-12-01 | Fujisawa Pharmaceutical Co | Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same |
| JPH03278050A (ja) * | 1990-03-27 | 1991-12-09 | Konica Corp | ハロゲン化銀写真感光材料 |
| JPH0473190A (ja) * | 1990-07-16 | 1992-03-09 | Konica Corp | 感熱転写記録材料 |
| WO1994005153A1 (en) | 1992-09-09 | 1994-03-17 | E.I. Du Pont De Nemours And Company | Herbicidal benzene compounds |
| BR9810385A (pt) * | 1997-07-01 | 2000-09-05 | Warner Lambert Co | Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek |
| JP2001526255A (ja) | 1997-12-23 | 2001-12-18 | ワーナー−ランバート・カンパニー | 炎症性疾患およびアテローム性動脈硬化症を治療または予防するチオ尿素およびベンズアミド化合物、組成物並びに方法 |
| MXPA02008103A (es) * | 2000-03-15 | 2002-11-29 | Warner Lambert Co | Diarilaminas sustituidas con 5-amida como inhibidores mek. |
| EP1339702A1 (en) * | 2000-03-15 | 2003-09-03 | Warner-Lambert Company | 5-amide substituted diarylamines as mek inhibitors |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| AU2003220935A1 (en) | 2002-04-03 | 2003-10-13 | Sumitomo Pharmaceuticals Company, Limited. | Benzamide derivatives |
| WO2004035037A2 (en) * | 2002-10-21 | 2004-04-29 | Ramot At Tel Aviv University Ltd. | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| JP4220548B2 (ja) * | 2003-06-05 | 2009-02-04 | エラン ファーマシューティカルズ，インコーポレイテッド | アシル化されたアミノ酸・アミジルピラゾール、および関連化合物 |
| US7504401B2 (en) * | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| FR2862965B1 (fr) * | 2003-11-27 | 2007-09-07 | Merck Sante Sas | Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides. |
| CA2589495C (en) * | 2004-12-15 | 2013-10-01 | Dompe Pha.R.Ma. S.P.A. | 2-arylpropionic acid derivatives and pharmaceutical compositions containing them |
| CA2602854C (en) | 2005-04-01 | 2013-05-14 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| TWI396543B (zh) | 2005-05-12 | 2013-05-21 | Sankyo Co | 取代丙烯醯胺衍生物及含有它之醫藥組成物 |
| MX295245B (es) * | 2005-06-21 | 2012-01-26 | Mitsui Chemicals Inc | Derivado de amida e insecticida que contiene el mismo. |
| EP1754483A1 (en) | 2005-08-18 | 2007-02-21 | Merck Sante | Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them |
| WO2007044565A2 (en) | 2005-10-06 | 2007-04-19 | University Of Massachusetts | Composition and synthesis of new reagents for inhibition of hiv replication |
| GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
-
2008
- 2008-07-22 GB GBGB0813403.3A patent/GB0813403D0/en not_active Ceased
-
2009
- 2009-07-20 DK DK09785362T patent/DK2310357T3/da active
- 2009-07-20 WO PCT/GB2009/050887 patent/WO2010010380A1/en not_active Ceased
- 2009-07-20 JP JP2011519241A patent/JP2011529037A/ja active Pending
- 2009-07-20 CN CN2009801378414A patent/CN102159535A/zh active Pending
- 2009-07-20 EP EP09785362.6A patent/EP2310357B1/en active Active
- 2009-07-20 US US13/054,960 patent/US9464052B2/en active Active
-
2016
- 2016-09-08 US US15/259,064 patent/US9675567B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529037A5 (https=) | ||
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| NZ610151A (en) | Salts and crystalline forms of an apoptosis-inducing agent | |
| CA2601508A1 (en) | Cyclopropanecarboxamide derivatives | |
| NZ724602A (en) | Ror-gamma modulators and uses thereof | |
| JP2014502979A5 (https=) | ||
| NZ708508A (en) | Methods of treatment using selective bcl-2 inhibitors | |
| RU2014115427A (ru) | Фармацевтические композиции замещенных хиназолинонов | |
| NZ603198A (en) | Novel hydroxamic acid derivative | |
| JP2009528296A5 (https=) | ||
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| JP2013510122A5 (https=) | ||
| NZ614305A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
| JP2014511892A5 (https=) | ||
| MX2011013164A (es) | Forma de sosis farmaceutica para administracion oral de un inhibidor de la familia bcl-2. | |
| JP2009541443A5 (https=) | ||
| JP2007519754A5 (https=) | ||
| WO2012122865A3 (zh) | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| JP2010520168A5 (https=) | ||
| JP2018048143A5 (https=) | ||
| CA2554550A1 (en) | Hydroisoindoline tachykinin receptor antagonists | |
| JP2017509694A5 (https=) | ||
| JP2008537547A5 (https=) |